In the retrospective study by Xiang et al., the median PFS of EGFR mutant NSCLC patients with gradual progression following first-line EGFR TKI who received anlotinib was 6.7 months compared to 3.6 months for those on continued EGFR TKI alone (Xiang et al., 2024). Here, EGFR is linked to non-small cell lung carcinoma.